<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rodriguez-Ruiz ME</submitter><funding>Cancer Research UK</funding><funding>Instituto de Salud Carlos III</funding><funding>Ministerio de Ciencia e Innovacion and the Agencia Estatal de Investigacion</funding><funding>Fundacion cientifica asociación española contra el cancer</funding><funding>CRIS Investigator grant</funding><pagination>e005011</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9835951</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Radioimmunotherapy combines irradiation of tumor lesions with immunotherapy to achieve local and abscopal control of cancer. Most immunotherapy agents are given systemically, but strategies for delivering immunotherapy locally are under clinical scrutiny to maximize efficacy and avoid toxicity. Local immunotherapy, by injecting various pathogen-associated molecular patterns, has shown efficacy both preclinically and clinically. BO-112 is a viral mimetic based on nanoplexed double-stranded RNA (poly I:C) which exerts immune-mediated antitumor effects in mice and humans on intratumoral delivery. BO-112 and focal irradiation were used to make the proof-of-concept for local immunotherapy plus radiation therapy combinations.&lt;h4>Methods&lt;/h4>Murine transplantable tumor cell lin</pubmed_abstract><journal>Journal for immunotherapy of cancer</journal><pubmed_title>Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.</pubmed_title><pmcid>PMC9835951</pmcid><funding_grant_id>N/A</funding_grant_id><funding_grant_id>PI20/00434</funding_grant_id><funding_grant_id>PR_TCL_2020-03</funding_grant_id><funding_grant_id>C18915/A29362</funding_grant_id><funding_grant_id>RTC2019-006860-1</funding_grant_id><pubmed_authors>Diaz Pascual V</pubmed_authors><pubmed_authors>Alvarez M</pubmed_authors><pubmed_authors>Barrio-Alonso C</pubmed_authors><pubmed_authors>Serrano-Mendioroz I</pubmed_authors><pubmed_authors>Quintero M</pubmed_authors><pubmed_authors>Melero I</pubmed_authors><pubmed_authors>Perez-Gracia JL</pubmed_authors><pubmed_authors>Garate-Soraluze E</pubmed_authors><pubmed_authors>Sanchez-Mateos P</pubmed_authors><pubmed_authors>Rodriguez Lopez I</pubmed_authors><pubmed_authors>Arbea Moreno L</pubmed_authors><pubmed_authors>Rodriguez-Ruiz ME</pubmed_authors><pubmed_authors>Escuin-Ordinas H</pubmed_authors><pubmed_authors>Sanmamed MF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.</name><description>&lt;h4>Background&lt;/h4>Radioimmunotherapy combines irradiation of tumor lesions with immunotherapy to achieve local and abscopal control of cancer. Most immunotherapy agents are given systemically, but strategies for delivering immunotherapy locally are under clinical scrutiny to maximize efficacy and avoid toxicity. Local immunotherapy, by injecting various pathogen-associated molecular patterns, has shown efficacy both preclinically and clinically. BO-112 is a viral mimetic based on nanoplexed double-stranded RNA (poly I:C) which exerts immune-mediated antitumor effects in mice and humans on intratumoral delivery. BO-112 and focal irradiation were used to make the proof-of-concept for local immunotherapy plus radiation therapy combinations.&lt;h4>Methods&lt;/h4>Murine transplantable tumor cell lin</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-06-14T07:51:00.007Z</modification><creation>2025-04-04T14:30:24.722Z</creation></dates><accession>S-EPMC9835951</accession><cross_references><pubmed>36631161</pubmed><doi>10.1136/jitc-2022-005011</doi></cross_references></HashMap>